These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18838439)

  • 21. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
    Oudard S
    Anticancer Res; 2010 Dec; 30(12):5223-5. PubMed ID: 21187517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
    Grundbichler M; Mlineritsch B; Ressler S; Moik M; Kappacher A; Rosenlechner S; Greil R
    Oncology; 2011; 80(1-2):34-41. PubMed ID: 21606662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Renal cell carcinoma].
    Obara W; Fujioka T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
    Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Siebels M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Wood LS
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():13-8. PubMed ID: 19948455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
    Porta C
    Br J Cancer; 2010 Mar; 102(7):1196-7. PubMed ID: 20179707
    [No Abstract]   [Full Text] [Related]  

  • 37. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical resection of renal cell carcinoma after targeted therapy.
    Thomas AA; Rini BI; Stephenson AJ; Garcia JA; Fergany A; Krishnamurthi V; Novick AC; Gill IS; Klein EA; Zhou M; Campbell SC
    J Urol; 2009 Sep; 182(3):881-6. PubMed ID: 19616232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.